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Objectives: To determine the use of the mucin
proteins MUC5B and MUC5AC as prognosis markers
for non-small cell lung cancer (NSCLC) carrying
epidermal growth factor receptor (EGFR) mutations.
Setting: Patients who underwent surgical resection at
Nagasaki University Hospital and related facilities in
Japan between June 1996 and March 2013.
Participant: 159 Japanese patients (male: n=103;
female: n=56) with NSCLC, who underwent surgical
resection (EGFR-mutant type: n=78, EGFR wild type:
n=81).
Results: Patients whose tumours expressed MUC5B
had significantly longer overall survival and relapse-free
survival compared to the MUC5B-negative patients with
EGFR mutant NSCLC (p=0.0098 and p=0.0187,
respectively). In patients with EGFR wild-type NSCLC,
there was no association with MUC5B expression.
MUC5AC expression was not different between EGFR
mutant and wild-type NSCLC.
Conclusions: Present findings indicate that MUC5B,
but not MUC5AC, is a novel prognostic biomarker for
patients with NSCLC carrying EGFR mutations but not
for patients with NSCLC carrying wild-type EGFR.
INTRODUCTION
Lung cancer is the primary cause of cancer-
related death in the USA and worldwide.1
Non-small cell lung cancer (NSCLC)
accounts for approximately 80–85% of all
lung cancers.1 Currently, targeted therapies
for non-resectable NSCLC have progressed
rapidly, based on the discovery of pharmaco-
logically treatable driver mutations in epider-
mal growth factor receptor (EGFR) and
fusions of anaplastic lymphoma kinase
(ALK).2 3 These moleculary targeted therap-
ies have revealed distinct and/or overlapping
tumorigenic pathways associated with each
driver mutation, especially regarding the
mechanisms of tumour recurrence.4 Genetic
screening of driver mutations, including
EGFR mutations and ALK fusions, is now
common for metastatic NSCLC but not for
surgically resected primary NSCLC.5 In the
ALCHEMIST lung cancer trials (http://www.
cancer.gov/researchandfunding/areas/clinical-
trials/nctn/alchemist), patients whose primary
lung tumours carry EGFR mutations (EGFR-
mutant patients) are being tested for adjuvant
therapy of erlotinib targeting EGFR muta-
tions. However, a favourable or poor prognos-
tic biomarker associated with EGFR mutations
is not known. Such biomarkers will be useful
to determine EGFR-mutant patients who
would benefit most from the adjuvant therapy
of erlotinib and to avoid such unnecessary
therapy after surgery in patients who would
not benefit.
Recently, we reported that decreased
expression of Nkx2–1 (also known as TTF-1)
in a mouse model of EGFR mutant NSCLC
reduced the number and size of lung
tumours,6 and extended the survival of the
mice (see online supplementary figure S1).
Unexpectedly, the decreased Nkx2–1
induced the expression of a mucin protein
MUC5B but not MUC5AC in EGFR-mutant
Strengths and limitations of this study
▪ A prognostic marker for each driver mutation in
non-small cell lung cancer (NSCLC) has not yet
been determined.
▪ MUC5B is a favourable postoperative prognostic
marker for epidermal growth factor receptor
(EGFR) mutant NSCLC.
▪ MUC5AC is not correlated with postoperative
prognosis regardless of EGFR mutation status.
▪ The function of MUC5B in EGFR mutant NSCLC
remains unknown.
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lung tumours in the mice,6 suggesting that MUC5B may
serve as a favourable prognostic marker associated with
EGFR mutant NSCLC in humans. In the present study,
we assessed whether the expression of MUC5B in the
primarily resected EGFR mutant or wild-type lung
tumours is linked to survival of the patients after
surgery. Our study provides a novel approach to assess
prognosis for patients whose primarily resected lung
tumours carry EGFR mutations.
METHODS
Study population
Among the patients who underwent surgical resection at
Nagasaki University Hospital and related facilities
between June 1996 and March 2013, patients who were
tested for the presence or absence of EGFR mutations
were selected for this study. The EGFR mutations were
confirmed internally or externally (LSI Medience
Corporation, Japan). We further selected the patients
whose clinicopathological characteristics were retrieved
from the patients’ charts and whose prognosis was fol-
lowed at our institution and related facilities. We
enrolled 159 patients (EGFR-mutant type: n=78, EGFR
wild type: n=81) for this study (table 1). All investiga-
tions were approved by our institution and related facil-
ities’ review boards, and informed consent was obtained
from all participants prior to the study.
Clinicopathological evaluation
Histological classification of NSCLC was designated as
three types—well, moderately and poorly differentiated
—based on the predominant features according to the
WHO classification.7 The patients remained for a
median follow-up period of 1680 days, ranging from 55
to 4503 days. For all patients, periodic inspection with
chest X-ray, CT scan and tumour marker assays was per-
formed at least every 6 months to confirm the presence
or absence of recurrence, even if patients experienced
no problems or no symptoms.
Antibody information
For immunohistochemical staining, primary antibodies
were used at the following concentrations: rabbit poly-
clonal anti-MUC5B (1:200; sc-20 119, Santa Cruz
Biotechnology) and rabbit polyclonal anti-MUC5AC
(1:50; sc-20 118, Santa Cruz Biotechnology).
Sample preparation, selection and immunohistochemistry
The 5 µm thick formalin-fixed paraffin-embedded
(FFPE) lung sections were deparaffinised in dimethyl-
benzene and dehydrated through a graded alcohol
series. For antigen retrieval, the FFPE lung sections were
incubated in 10 mM citric acid (pH 6) at 121°C for
15 min and then washed in phosphate-buffered saline
(PBS). Next, the lung sections were immersed in 3%
H2O2 solution for 30 min to block the endogenous per-
oxidase followed by incubation with each primary
antibody at 4oC overnight. After washing in PBS, the
lung sections were incubated with the peroxidase-
conjugated secondary antibodies (Simple Stain MAX-PO
kit, Nichirei, Tokyo, Japan) for 30 min at room tempera-
ture. For immunohistochemistry (IHC) staining, the
lung sections were visualised with a diaminobenzidine
(DAB: brown) kit (Histofine, Nichirei) and counter-
stained with H&E. The lung sections visualised with
Table 1 Baseline characteristics of the 159 patients with
NSCLC
Number of patients








Adenocarcinoma: bronchoalveolar 33 (21%)
Adenocarcinoma 91 (57%)
Squamous cell carcinoma 32 (20%)
Adenosquamous carcinoma 2 (1%)
Other* 1 (1%)




























Wild type 81 (51%)
Mutant type 78 (49%)
Data are median (range) or number (%) unless otherwise stated.
*Other mean NSCLC neuroendocrine.
EGFR, epidermal growth factor receptor; MD, missing data;
NSCLC, non-small cell lung cancer.
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DAB were dehydrated with alcohol and dimethylben-
zene and mounted in a conventional fashion.
Normal bronchial tissue specimens that moderately
expressed MUC5B were prepared as positive controls in
all cases. Normal gastric mucosa tissue specimens that
moderately expressed MUC5AC were prepared as posi-
tive controls in all cases. Negative controls were also pre-
pared in all cases. MUC5B and MUC5AC staining was
evaluated by IHC by two independent trained observers
(KW and TT). The pathological criteria were deter-
mined by reference to guideline for human epidermal
growth factor receptor 2 (Her2/neu) testing in breast
cancer (score 0, no staining observed or incomplete
faint/barely perceptible cytoplasmic staining of <10% of
tumour cells; score 1, incomplete faint/barely percep-
tible cytoplasmic staining of >10% of tumour cells;
score 2, incomplete weak/moderate cytoplasmic staining
of >10% of tumour cells; score 3, complete and intense
cytoplasmic staining of >30% of tumour cells).8 Scores 0
and 1 were further categorised as negative, and scores 2
and 3 as positive.
Statistical analysis
For univariate analysis, categorical data were analysed by
the χ2 test, Fisher’s exact test or the Cochran-Armitage
test. Continuous data were expressed as a mean using
the Mann-Whitney U test or the Kruskal-Wallis test. The
overall survival (OS) and relapse-free survival (RFS)
were calculated according to the Kaplan-Meier method,
and differences between groups were tested for signifi-
cance using the log-rank test. Participants who neither
died nor had recurrence were censored at the time of
their last follow-up. The prognostic relevance of a single
factor was determined by multivariate Cox regression
analysis. A p value of 0.05 or less was considered signifi-
cant. SPSS V.17 software (SPSS Japan, Tokyo, Japan) was
used for the analysis.
RESULTS
Expression of MUC5B and MUC5AC in human NSCLC
Since MUC5B is an abundant cytoplasmic and secreted
protein, we assessed whether MUC5B could be used as a
prognostic marker for patients with NSCLC carrying
EGFR mutations in primary resected human lung
tumours. Primary resected NSCLC tumours were tested
immunohistochemically for the presence of MUC5B.
MUC5B staining was detected in the cytoplasm of
NSCLC cells in 27 of the 78 samples with EGFR muta-
tions and 29 of the 81 samples with wild-type EGFR
(figure 1A, B). The NSCLC samples were also tested
using MUC5AC antibody, detecting expression of
MUC5AC in the cytoplasm of NSCLC cells in 20 of the
73 samples with EGFR mutations and 24 of the 79
samples with wild-type EGFR (figure 1C, D). These
results indicate that both MUC5B and MUC5AC are
expressed in a portion of human NSCLC.
Prognostic association of MUC5B or MUC5AC with EGFR
mutant or wild-type NSCLC
Expression of MUC5B in NSCLC tumours carrying
EGFR mutations was not correlated with clinicopatholo-
gical parameters, including age, gender, smoking status,
histological type, tumour size, degree of differentiation,
stage, tumour status, nodal status, lymphatic invasion,
venous invasion or adjuvant chemotherapy (table 2).
Expression of MUC5B in NSCLC tumours with wild-type
EGFR was not correlated with all of the clinicopathologi-
cal parameters but was correlated with the histological
type (see online supplementary table S1).
OS and RFS for patients with NSCLC carrying EGFR
mutations or wild-type EGFR were assessed. In a cohort
of patients whose resected NSCLC tumours carried
EGFR mutations, univariate analysis showed significant
differences (p<0.05) in OS in expression of MUC5B,
tumour size, histological type, degree of differentiation,
stage, lymphatic invasion and venous invasion, and in
RFS in expression of MUC5B, tumour size, degree of dif-
ferentiation, stage, lymphatic invasion and venous inva-
sion (table 3). Patients whose tumours expressed
MUC5B (MUC5B-positive patients) survived significantly
longer than patients whose tumours did not express
MUC5B (MUC5B-negative patients) in both OS (5-year
OS; 95.8% vs 65.1%, p=0.0098; figure 2A) and RFS
(5-year RFS; 69.9% vs 44%, p=0.0187; figure 2B).
Figure 1 Immunohistochemical
staining for MUC5B and
MUC5AC expression in NSCLC.
Representative images of
immune-positive staining for
MUC5B in non-small cell lung
cancer (A), negative staining (B),
positive staining for MUC5AC (C)
and negative staining (D).
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Multivariate Cox regression analysis using the variables
that were p<0.05 in univariate analysis showed that the
expression of MUC5B was independently associated with
better OS and RFS (p<0.05; table 4). In a cohort of
patients whose resected NSCLC tumours had wild-type
EGFR, univariate analysis showed significant differences
(p<0.05) in OS in smoking status, stage, venous invasion
and adjuvant chemotherapy, and in RFS, lymphatic inva-
sion and venous invasion (see online supplementary
table S2). There was no significant difference between
the MUC5B-positive patients and MUC5B-negative
patients in OS and RFS (5-year OS; 59.5% vs 63.6%,
5-year RFS; 36% vs 48.5%, respectively, figure 2C, D).
Expression of MUC5AC in NSCLC was not associated
with OS and RFS regardless of EGFR mutation status
(figure 3). These results indicate that MUC5B is a
favourable prognostic marker for postoperative patients
whose resected NSCLC tumours carry EGFR mutation
but not for those with wild type-EGFR.
DISCUSSION
In the present study, we demonstrate that expression of
MUC5B in primary EGFR mutant NSCLC is associated
with longer survival in patients with NSCLC. MUC5B,
but not MUC5AC, is a favourable prognostic biomarker
for NSCLC in humans carrying EGFR mutations. Our
study also indicates that adjuvant chemotherapy is not




Total Negative (−) Positive (+)
(n=78) (n=51) (n=27)
Median age (range, years) 66.9 (41–85) 66.7 (42–83) 67.3 (41–85) 0.674
Gender
Male 35 (45%) 22 (28%) 13 (17%)
Female 43 (55%) 29 (37%) 14 (18%) 0.6721
Smoking status
Non-smoker 42 (54%) 28 (36%) 14 (18%)
Smoker 36 (46%) 23 (29%) 13 (17%) 0.7971
Histological type
Adenocarcinoma: bronchoalveolar 27 (35%) 16 (21%) 11 (14%)
Adenocarcinoma 43 (55%) 29 (37%) 14 (18%)
Squamous cell carcinoma 8 (10%) 6 (8%) 2 (3%) 0.6522
Median tumour size (range, mm) 25.7 (8–60) 26.1 (8–60) 24.9 (8–50) 0.8771
Degree of differentiation
Well 35 (45%) 22 (28%) 13 (17%)
Moderately 28 (36%) 19 (24%) 9 (12%)
Poorly 11 (14%) 6 (8%) 5 (6%) 0.7348
MD 4 (5%) 4 (5%) 0 (0%)
Stage
IA/IB 46 (59%) 29 (37%) 17 (22%)
IIA/IIB 14 (18%) 8 (10%) 6 (8%)
IIIA/IIIB 18 (23%) 14 (18%) 4 (5%) 0.4162
Tumour status
T1–2 68 (87%) 42 (54%) 26 (33%)
T3–4 10 (13%) 9 (12%) 1 (1%) 0.0797
Nodal status
N0 53 (68%) 35 (45%) 18 (23%)
N1–3 25 (32%) 16 (21%) 9 (12%) 0.8599
Lymphatic invasion
Negative 35 (45%) 26 (33%) 9 (12%)
Positive 42 (54%) 24 (31%) 18 (23%) 0.1165
MD 1 (1%) 1 (1%) 0 (0%)
Venous invasion
Negative 45 (58%) 30 (38%) 15 (19%)
Positive 32 (41%) 20 (26%) 12 (15%) 0.7057
MD 1 (1%) 1 (1%) 0 (0%)
Adjuvant chemotherapy
Yes 33 (42%) 20 (26%) 13 (17%)
No 45 (58%) 31 (40%) 14 (18%) 0.4475
Data are median (range) or number (%) unless otherwise stated.
EGFR, epidermal growth factor receptor; MD, missing data; NSCLC, non-small cell lung cancer.
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effective for EGFR-mutant patients, suggesting that
mutant EGFR-targeting drugs, including gefitinib or
erlotinib, should be used as an adjuvant therapy mainly
for MUC5B-negative EGFR-mutant patients who have a
poorer prognosis than MUC5B-positive EGFR-mutant
patients. Our results using MUC5B as a prognosis bio-
marker for EGFR-mutant patients should be integrated
into the ALCHEMIST lung cancer trials to determine
patients who would benefit most from the adjuvant
therapy.
MUC5B has been assessed as a prognostic biomarker
for multiple cancers in several studies, using reverse
transcription-PCR, microarray analysis and IHC (see
online supplementary table S3).9–14 Messenger RNA
(mRNA) data assessing MUC5B as a prognostic bio-
marker is available at PrognoScan, a database for
meta-analysis of the prognostic value of genes using
microarray data deposited to the public domain.15 The
prognostic impact of MUC5B expression differed among
cancer types. In lung cancer, six microarray studies
analysed by PrognoScan did not indicate MUC5B as
either a good or a poor prognostic biomarker.16–21
Immunohistochemical analysis indicated MUC5B as a
poor prognosis biomarker (see online supplementary
table S3), 9 14 a finding contradicting our present study.
Previous mRNA microarray and immunostaining were
based on all NSCLCs independent of driver mutation-
based classification, which differs from our analysis,
which was based on classification by EGFR mutations.
The utility of MUC5B as a prognostic factor differed in
the two breast cancer studies, depending on the molecu-
lar basis of the tumours. In all breast cancers,
PrognoScan indicated that MUC5B was associated with
poor prognosis;22 23 however, in (estrogen receptor-)
positive breast cancers, MUC5B was associated with
favourable prognosis,24 indicating the potential
Table 3 Univariate analysis for OS and RFS in EGFR-mutant patients with NSCLC
Parameters N
OS RFS
Survival (%) p Value Survival (%) p Value
Age (years)
<70 39 75.5 63.6
≥70 39 76.3 0.7311 41.5 0.1207
Gender
Male 35 69 54.4
Female 43 81.5 0.3166 51.8 0.813
Smoking status
Non-smoker 43 75.9 49.1
Smoker 36 73.3 0.9754 55.8 0.8508
MUC5B expression
Positive 27 95.8 69.9
Negative 51 65.1 0.0098 44 0.0187
Tumour size
<20 mm 25 95 85.7
≥20 mm 44 64.4 0.0058 31.2 0.0001
Histological type
Adenocarcinoma 69 78.8 54
Squamous cell carcinoma 8 46.9 0.0245 50 0.6369
Degree of differentiation
Well 35 90 72.6
Moderately 28 62.3 34.5
Poorly 11 50.6 0.0172 38.1 0.0137
Stage
I 45 87.8 62.8
II/III 33 59.3 0.0095 38.8 0.0308
Lymphatic invasion
Negative 35 92.3 74.2
Positive 42 62.7 0.0075 35.8 0.0011
Venous invasion
Negative 45 89 66.5
Positive 32 55.7 0.0045 25.9 0.0021
Adjuvant chemotherapy
Yes 33 62 37.5
No 45 82.8 0.2569 63.4 0.0183
Data are p values by Kaplan-Meier analysis.
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; RFS, relapse-free survival.
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importance of tumour classification on a molecular
basis. In the present study, we assessed MUC5B as a bio-
marker for NSCLC based on EGFR mutation status
rather than on all NSCLCs, identifying MUC5B as a
favourable prognosis biomarker for EGFR mutant
NSCLC.
Regulation of MUC5B in EGFR mutant NSCLC is not
well understood. MUC5AC and MUC5B genes are closely
located at a locus on human chromosome 11. Both are
evolutionally conserved gel-forming mucins secreted
from airway epithelial cells in the lung. In normal lung,
MUC5B is constitutively expressed at higher levels than
MUC5AC.25 In asthma and other inflammatory lung dis-
eases, MUC5AC is highly induced in airway goblet
cells.25 In idiopathic pulmonary fibrosis (IPF), MUC5B
but not MUC5AC is highly expressed in the airway
goblet cells.26 27 The single-nucleotide polymorphism
(SNP) rs35705950 located at the MUC5B promoter is
associated with induction of MUC5B mRNA in IPF;27
however, we detected the SNP rs35705950 in only one of
27 cases in the EGFR mutant NSCLC expressing MUC5B
(data not shown), indicating that the SNP is not asso-
ciated with increased MUC5B in EGFR mutant NSCLC.
Since MUC5B was induced in EGFR mutant lung
tumours in Nkx2–1 heterozygous mice (EGFRL858R;
Nkx2–1+/−), Muc5b is suppressed by NKX2–1 in EGFR
mutant NSCLC in mice.6 Regulatory mechanisms con-
trolling the MUC5B gene are not understood in EGFR
mutant NSCLC in humans. The function of MUC5B in
cancer has been analysed using a truncated MUC5B in
MCF7 breast cancer cells, truncated MUC5B promoting
tumourigenesis of MCF7 cells.13 However, the use of
truncated MUC5B may obscure the intrinsic role of full-
length MUC5B since there is a possibility that the trun-
cated MUC5B may function in a dominant-negative
fashion. In lung, MUC5B is required for mucociliary
Figure 2 Survival curves for patients based on the expression of MUC5B in epidermal growth factor receptor (EGFR) mutant or
wild-type non-small cell lung cancer (NSCLC). Overall and relapse-free survivals (OS and RFS) for patients with NSCLC carrying
EGFR mutations or EGFR wild type. OS (A) RFS (B) in the patients with EGF- mutant type NSCLC and OS (C) and RFS (D) in
the patients with EGFR wild-type NSCLC.
Table 4 Multivariate analysis for OS and RFS in EGFR-mutant patients with NSCLC
HR 95% CI p Value
OS
MUC5B (positive vs negative) 0.053 0.0064 to 0.4402 0.0065
Differentiation (well vs moderately vs poorly) 0.3762 0.1357 to 1.0428 0.0602
Stage I vs stage II/III 0.5199 0.1687 to 1.6019 0.2545
Lymphatic invasion (positive vs negative) 2.9524 0.6572 to 13.2631 0.1578
RFS
MUC5B (positive vs negative) 0.2913 0.1233 to 0.6886 0.005
Stage I vs stage II/III 0.5937 0.2735 to 1.2888 0.1874
Lymphatic invasion (positive vs negative) 3.7624 1.5294 to 9.2556 0.0039
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; RFS, relapse-free survival.
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clearance and innate immunity against bacterial infec-
tion.28 The potential functions of MUC5B in lung
cancer, including EGFR mutant lung cancer, are not
known. The present study suggests that MUC5B or pro-
cesses regulating MUC5B may influence the growth and
metastasis of EGFR mutant NSCLC. MUC5B may serve as
a surrogate biomarker influenced by a pathway involved
in metastasis and recurrence associated with EGFR
mutant NSCLC.
In conclusion, our data revealed the clinicopathologi-
cal significance of MUC5B as a favourable prognostic
factor in resected EGFR mutant NSCLC. Further studies
are necessary to elucidate the gene regulatory mechan-
ism and the function of MUC5B in EGFR mutant
NSCLC.
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